

**LEMBAR
HASIL PENILAIAN SEJAWAT SEBIDANG ATAU PEER REVIEW
KARYA ILMIAH : JURNAL ILMIAH INTERNATIONAL**

Judul Karya Ilmiah (Artikel)	: Toll Like Receptor 4 Expression Profile in Mice Infected Mycobacterium Tuberculosis Given with Miana Leaves Extract (<i>Coleus scutellarioides</i> (L.) Benth) (Tuberculosis Preventive and Curative Mechanisms)		
Nama Penulis	: Sesilia Rante Pakadang , St Ratnah , Alfrida Monica Salasa, Jumain, Mochammad Hatta		
Jumlah Penulis	: 5 orang		
Status Pengusul	: Penulis Ke 2		
Identitas Jurnal /Artikel	a. Nama Jurnal	: <i>Pharmacognosy Journal</i>	
	b. Nomor ISSN	: 0975-3575	
	c. Volume, Nomor, Bulan, Tahun, hal	: Vol. 14, No. 3, Juni 2022, hal 497-505	
	d. Penerbit	: EManuscript Technologies	
	e. DOI artikel (jika ada)	DOI:10.5530/pj.2022.14.63	
	f. Alamat web jurnal	https://www.phcogj.com/v14/i3 https://www.phcogj.com/sites/default/files/PharmacognJ-14-3-497.pdf	
	g. Terindeks di	SJR : 0.268 https://www.scopus.com/sourceid/19700175096	
Kategori publikasi Jurnal Ilmiah (beri <input checked="" type="checkbox"/> pada kategori yang tepat)	<input checked="" type="checkbox"/> Jurnal Ilmiah Internasional Bereputasi (SJR > 0,10)		
	<input type="checkbox"/> Jurnal Ilmiah Internasional Bereputasi (SJR < 0,10)		
	<input type="checkbox"/> Jurnal Ilmiah International terindeks di Web of science clarivate analytics / kelompok emerging sources citation indeks (tidak terindeks SJR)		

Hasil penilaian <i>Peer Review</i> Komponen yang dinilai	Nilai Maksimal Jurnal Ilmiah			
	International Bereputasi (SJR>0,10)	International Bereputasi (SJR<0,10)	International (Tidak terindek SJR)	Nilai Akhir yang diperoleh
	Nilai 40	Nilai 30	Nilai 20	
a. Kelengkapan unsur isi jurnal ilmiah (10%)	4,0			4,0
b. Ruang lingkup dan kedalaman pembahasan (30%)	12			11,5
c. Kecukupan dan kemutahiran data/informasi dan metodologi (30%)	12			11,5
d. Kelengkapan unsur dan kualitas terbitan (30%)	12			12
Total = (100%)	40			39

Nilai Pengusul : $\frac{1}{4} \times 40 \% \times 39 = 3,9$

Catatan Peer Reviewer :

1. Tentang Kelengkapan Unsur isi

Artikel ditulis dengan baik sesuai dengan pedoman, semua literatur yang jadi acuan tertulis di Pustaka. Terdapat hubungan antara latar belakang, tujuan, pembahasan dan kesimpulan.

2. Ruang lingkup dan kedalaman pembahasan

Pembahasan yang disajikan sudah bagus karena topik sesuai dengan bidang ilmu penulis.
Pembahasan dilengkapi dengan artikel yang relevan dengan topik penelitian

3. Kecukupan dan Kemutakhiran data / informasi dan metodologi

Pustaka yang digunakan 5-10 tahun terakhir, metodologi yang digunakan sudah sesuai dengan tujuan penelitian dan analisis data

4. Kelengkapan unsur dan kualitas terbitan

Jurnal terbit konsisten 6 kali setahun, terbit secara online dan terindeks SJR 0,268


5. Indikasi Plagiasi

Tidak terdeteksi adanya indikasi plagiasi

6. Kesesuaian bidang ilmu

Sesuai bidang ilmu

Makassar, 20 September 2022
Reviewer 1


Nama : Dr. H. Ashari Rasjid, SKM, MS
NIP : 196307231983021001
Unit Kerja : Poltekkes Kemenkes Makassar
Jabatan Fungsional : Lektor Kepala
Bidang Ilmu : Kesehatan

LEMBAR
HASIL PENILAIAN SEJAWAT SEBIDANG ATAU PEER REVIEW
KARYA ILMIAH : JURNAL ILMIAH INTERNATIONAL

Judul Karya Ilmiah (Artikel)	: Toll Like Receptor 4 Expression Profile in Mice Infected Mycobacterium Tuberculosis Given with Miana Leaves Extract (<i>Coleus scutellarioides</i> (L.) Benth) (Tuberculosis Preventive and Curative Mechanisms)	
Nama Penulis	: Sesilia Rante Pakadang , St Ratnah , Alfrida Monica Salasa, Jumain, Mochammad Hatta	
Jumlah Penulis	: 5 orang	
Status Pengusul	: Penulis Ke 2	
Identitas Jurnal /Artikel	a. Nama Jurnal	: <i>Pharmacognosy Journal</i>
	b. Nomor ISSN	: 0975-3575
	c. Volume, Nomor, Bulan, Tahun, hal	: Vol. 14, No. 3, Juni 2022, hal 497-505
	d. Penerbit	: EManuscript Technologies
	e. DOI artikel (jika ada)	DOI:10.5530/pj.2022.14.63
	f. Alamat web jurnal	https://www.phcogi.com/v14/i3 https://www.phcogi.com/sites/default/files/PharmacognJ-14-3-497.pdf
	g. Terindeks di	SJR : 0.268 https://www.scopus.com/sourceid/19700175096
Kategori publikasi Jurnal Ilmiah (beri <input checked="" type="checkbox"/> pada kategori yang tepat)	<input checked="" type="checkbox"/> Jurnal Ilmiah Internasional Bereputasi (SJR > 0,10)	
	<input type="checkbox"/> Jurnal Ilmiah Internasional Bereputasi (SJR < 0,10)	
	<input type="checkbox"/> Jurnal Ilmiah International terindeks di Web of science clarivate analytics / kelompok emerging sources citation indeks (tidak terindeks SJR)	

Hasil penilaian <i>Peer Review</i> Komponen yang dinilai	Nilai Maksimal Jurnal Ilmiah			
	International Bereputasi (SJR>0,10)	International Bereputasi (SJR<0,10)	International (Tidak terindek SJR)	Nilai Akhir yang diperoleh
	Nilai 40	Nilai 30	Nilai 20	
a. Kelengkapan unsur isi jurnal ilmiah (10%)	4,0			4
b. Ruang lingkup dan kedalaman pembahasan (30%)	12			11
c. Kecukupan dan kemutahiran data/informasi dan metodologi (30%)	12			11
d. Kelengkapan unsur dan kualitas terbitan (30%)	12			12
Total = (100%)	40			38

Nilai Pengusul : $\frac{1}{4} \times 40\% \times 38 = 3.8$

Catatan Peer Reviewer :

1. Tentang Kelengkapan Unsur isi

Unsur isi artikel sudah lengkap dan sesuai dengan pedoman jurnal *Pharmacognosy*

2. Ruang lingkup dan kedalaman pembahasan

Ruang lingkup artikel sudah sesuai dengan bidang ilmu, pembahasan sudah melibatkan artikel yang relevan

3. Kecukupan dan Kemutakhiran data / informasi dan metodologi

Data sudah memadai, metode yang digunakan sudah sesuai dengan tujuan, design dan analisis data

4. Kelengkapan unsur dan kualitas terbitan

Unsur penerbit lengkap, kualitas terbitan bagus, jurnal terbit secara kontinyu

5. Indikasi Plagiasi

Tidak ada indikasi plagiasi

6. Kesesuaian bidang ilmu

Artikel sesuai dengan bidang ilmu farmasi

Makassar, 21 September 2022

Reviewer 2



Nama : Dr. Hj. Nurisyah, M.Si., Apt
NIP : 196505311986032001
Unit Kerja : Poltekkes Kemenkes Makassar
Jabatan Fungsional : Lektor Kepala
Bidang Ilmu : Farmasi



Source details

Pharmacognosy Journal

Scopus coverage years: from 2009 to Present

Publisher: Pharmacognosy Network Worldwide

ISSN: 0975-3575

Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmacology

Pharmacology, Toxicology and Pharmaceutics: Drug Discovery

Source type: Journal

CiteScore 2021

1.9



SJR 2021

0.258



SNIP 2021

0.718



[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology



CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021

$$1.9 = \frac{1,760 \text{ Citations 2018 - 2021}}{946 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022

$$1.6 = \frac{1,339 \text{ Citations to date}}{826 \text{ Documents to date}}$$

Last updated on 05 October, 2022 • Updated monthly

CiteScore rank 2021

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#219/303	27th
└ Pharmacology		
Pharmacology, Toxicology and Pharmaceutics	#116/154	25th
└ Drug Discovery		

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.





Phcogj.com

Pharmacognosy Journal (/)

An Open Access, Peer Reviewed Journal in the field of Pharmacognosy

Enter terms then hit Search...



Articles In Press (/inpress) Current Issue (/v14/i4) Archives (/archives)

RSS Feeds (/rss.xml) Submit Article (https://www.phcogj.info)



(http://www.facebook.com/#!/) (http://www.twitter.com/#!/)

View (/editorial-board-2020-21)

What links here (/node/25/backlinks)

Time to read
1 minute

Editorial Board (2020-21)

Editors & Editorial Board Members (2021)

Share



Dr.Djemli Samir
Department of Biology , Applied Neuroendocrinology Laboratory
Badr Mokhtar Annaba University
(https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.phcogj.com%2Feditorial-board-2020-21&t=Editorial+Board+%282020-21%29)



Dr. Raghava Naidu, Ph.D
Department of Human Oncology,
University of Wisconsin,
1111, Highland Ave, Madison,
Wisconsin 53705, USA
(https://plus.google.com/share?url=https%3A%2F%2Fwww.phcogj.com%2Feditorial-board-2020-21&t=Editorial+Board+%282020-21%29)

Dr. Karim Raafat

Associate Professor of Pharmacognosy and Phytochemistry,
Pharmaceutical Sciences Department,

2020-
21) Faculty of Pharmacy,
Beirut Arab University (BAU),
Beirut 115020, Lebanon



(<http://twitter.com/AbbasTantengco>, MD-PhD Molecular Medicine
text=Editorial+Board+%282020-
21%29&url=https%3A%2F%2Fwww.phcoji.com%2Feditorial-
board-
2020-
21) College of Medicine, University of the Philippines Manila
Pedro Gil Street, Ermita, Manila, Philippines, 1000

board-

2020-
21)

Janib Achmad

Lecturer of Faculty of Fisheries and Marine Science,
University of Khairun Ternate

Kampus 2 Jalan Pertamina, Kelurahan Gambesi,
Ternate Selatan



a- a+

Muammar Fawwaz, Ph.D

Department of Pharmaceutical Chemistry

Faculty of Pharmacy

Universitas Muslim Indonesia

Makassar 90231, South Sulawesi, Indonesia

Hany Ezzat Khalil

Associate Professor,
College of Clinical Pharmacy,
King Faisal University,
KSA

Emad Yousif

Department of Chemistry
College of Science
Al-Nahrain University
Baghdad, Iraq

Sughosh Upasani

R.C Patel Institute of pharmacy,
Shirpur, Dist-Dhule, Maharashtra,
India.

Gurusiddaiah suresh kumar

Scientist
Dept of biochemistry
CSIR-CFTRI
Mysore, Karnataka, INDIA

Arjun Patra

Assistant Professor
School of Pharmaceutical Sciences

Guru Ghasidas Central University
Koni, Bilaspur - 495 009
Chattisgarh, India

Francis O. Atanu, Ph.D

Department of Biochemistry
Faculty of Natural Sciences
Kogi State University
Anyigba, Nigeria.

Vijay Kumar Chattu

Faculty of Medical Sciences
University of the West Indies
St. Augustine, Trinidad & Tobago.

Dr.Kunle Okaiyeto, PhD

Applied and Environmental Microbiology Research Group (AEMREG)
Department of Biochemistry and Microbiology
University of Fort Hare
Alice campus
5700, Alice
South Africa.

Dr. Srisailam Keshetti, Ph.D

Principal, University College of Pharmaceutical Sciences, Satavahana University
Karimnagar 505001
Telangana
INDIA

Dr. Gayathri M Rao

Associate Professor
Department of Biochemistry
Kasturba Medical Collge, Mangaluru.

Shuge Tian

Experimental Teaching Demonstration Center of TCM in Xinjiang Medical
University
Department of traditional medicine ,TCM
Xinjiang Medical University
Xinjiang CHINA 830054

Dr. Ramachandra Setty Siddamsetty,

Professor, Govt College of Pharmacy,
Mission Road, Bengaluru, INDIA

Dr. (Mrs.) Sayyada Khaton

HOD, Pharmacognosy Division
CSIR-National Botanical Research Institute,
Rana Pratap Marg, Post Box 436,
Lucknow-226001 (U.P.) India

Dr. A. Sajeli Begum

Department of Pharmacy
Birla Institute of Technology & Science
Hyderabad, India

Olga Silva

Department of Pharmacological Sciences,
Faculdade de Farmácia,
Universidade de Lisboa, Portugal

Xinwen Wang

Department of Clinical Pharmacy
University of Michigan
USA

Roman Lysiuk

Department of Pharmacognosy and Botany,
Danylo Halytsky Lviv National Medical University,
Pekarska,69., Lviv 79010, Ukraine

Arif Nur Muhammad Ansori

Universitas Airlangga
Indonesia

99247 reads

SHARE THIS ARTICLE

EMAIL (MAILTO:?SUBJECT=EDITORIAL%20BOARD%20%282020-21%29&BODY=HTTPS%3A%2F%2FWWW.PHCOGJ.COM%2FEDITORIAL-BOARD-2020-21)

(HTTPS://WWW.PHCOGJ.COM/EDITORIAL-BOARD-2020-21)
U=HTTPS://WWW.PHCOGJ.COM/EDITORIAL-BOARD-2020-21&TITLE=EDITORIAL-BOARD-2020-21&URI=HTTPS://WWW.PHCOGJ.COM/EDITORIAL-BOARD-2020-21&TITLE=EDITORIAL-BOARD-2020-21

About

Pharmacognosy Journal (Phcog J.) covers different topics in natural product drug discovery, and also publishes manuscripts that describe pharmacognostic investigations, evaluation reports, methods, techniques and applications of all forms of medicinal plant research

Distinctions: The most widely read, cited, and known Pharmacognosy journal and website is well browsed with all the articles published. More than 50,000 readers in nearly every country in the world each month

ISSN : 0975-3575 ; Frequency : Rapid at a time publication (6 issues/year)

Indexed and Abstracted in : SCOPUS, Scimago Journal Ranking, Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Index Copernicus, Ulrich's International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.

Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.

Open Access Journal: Pharmacognosy Journal is an open access journal, which allows authors to fund their article to be open access from publication.

Submit your Next Article

- Online submission
- Highly indexed and abstracted
- 10 years of successful publishing
- Wider visibility though open access
- Higher impact with wider visibility
- Prompt review

Submit your next article to Phcog J

and be a part of many successful authors.

Create free account (<http://phcogj.info>) / [Login](#)
(<https://www.phcogj.com/submissions/index.php/phcogj/index>)

Copyright © 2020 Pharmacogn J. All rights reserved.

Pharmacognosy Journal and its contents are licensed under a Creative Commons Attribution-Non Commercial-No Derivs 4.0 License. Permissions beyond the scope of this license may be available with editor@phcogj.com (<mailto:editor@phcogj.com>)

[Home \(/\)](#)

[Advertise with us \(/\)](#)

Privacy Statement (/)

Pharmacognosy Journal (/)

An Open Access, Peer Reviewed Journal in the field of
Pharmacognosy


Enter terms then hit Search...

[Articles In Press \(/inpress\)](#)[Current Issue \(/v14/i4\)](#)[Archives \(/archives\)](#)[RSS Feeds \(/rss.xml\)](#)[Submit Article \(https://www.phcogj.info\)](https://www.phcogj.info)

HOME (/) / PHARMACOGNOSY JOURNAL,
VOL 14, ISSUE 3, MAY-JUN, 2022

Pharmacognosy Journal, Vol 14, Issue 3, May-Jun, 2022

RECENT ARTICLES



Original Article

The Effect of Pomegranate Peel Ethanol Extract to TNF- α Expression of Mice Colonic Epithelial Cells Induced Using Dextran Sodium Sulfate (DSS) (/article/1793)

Kusmardi Kusmardi,Raja Yasmin Khalilah,E Zuraidah,Ari Estuningtyas,Aryo Tedjo

Pharmacognosy Journal,14(3):480-488

DOI: 10.5530/pj.2022.14.61

Published: Wed, 29-Jun-2022

[Read More \(/article/1793\)](#)



Azadirachta indica Hexane Extract: Potent Antibacterial Activity Against Propionibacterium acne and Identification of its Chemicals Content (/article/1794)

Annysa Ellycornia Silvyana,Ratika Rahmasari,Berna Elya

Pharmacognosy Journal,14(3):489-496

DOI: 10.5530/pj.2022.14.62

Published: Thu, 30-Jun-2022

[Read More \(/article/1794\)](#)



Original Article

Toll Like Receptor 4 Expression Profile in Mice Infected Mycobacterium Tuberculosis Given with Miana Leaves Extract (Coleus scutellarioides (L.) Benth) (Tuberculosis Preventive and Curative Mechanisms) (/article/1795)


Sesilia Rante Pakadang,St. Ratnah,Alfrida Monica Salasa, Mochammad Hatta

Pharmacognosy Journal,14(3):497-505

DOI: 10.5530/pj.2022.14.63

Published: Mon, 27-Jun-2022

[Read More \(/article/1795\)](#)



[\(/article/1795\)](#)

Original Article

Effective Enzyme-Producing Bacteria Isolated from Diversified Thai Rice and Native Thai Bees (Cavity Nesting Honey Bees) and their Potential for Production of Protease Enzymes (/article/1796)

Thapakorn Chumphon,Yaowanoot Promnuan,Sujinan Meelai,Saran Promsai

Pharmacognosy Journal,14(3):506-517

DOI: 10.5530/pj.2022.14.64

Published: Mon, 27-Jun-2022

[Read More \(/article/1796\)](#)



Original Article



Antihypercholesterolemic Power of Red Dragon Fruit (*Hylocereus polyrhizus*) Peel Extract (/article/1797)


Ruqiah Ganda Putr Panjaitan, Syafira Amelia

Pharmacognosy Journal, 14(3):518-523

DOI: 10.5530/pj.2022.14.65

Published: Mon, 27-Jun-2022

[Read More \(/article/1797\)](#)



Original Article

Effects of High Intensity Swimming on Heat Shock Protein 70, Superoxide Dismutase and Malondialdehyde of Rattus norvegicus Male Rats (/article/1798)


Dody Taruna, Bambang Purwanto, Harianto Notopuro, Budi Utomo, Lilik Herawati, Reny I'tishom,

Pharmacognosy Journal, 14(3):524-530

DOI: 10.5530/pj.2022.14.66

Published: Thu, 30-Jun-2022

[Read More \(/article/1798\)](#)



Original Article

Subchronic Toxicity Studies of a Combined Andrographis paniculata (Burm.f.) Nees, Syzygium cumini (L) Skeels, and Caesalpinia sappan L Extract in Sprague-Dawley Rats (/article/1799)

Atini Solawati, Berna Elya, Heri Setiawan, Raysa Yunda Pratiwi

Pharmacognosy Journal, 14(3):531-535

DOI: 10.5530/pj.2022.14.67

Published: Tue, 28-Jun-2022

[Read More \(/article/1799\)](#)



Original Article

Utilization of Secondary Metabolites in Algae Kappaphycus alvarezii as a Breast Cancer Drug with a Computational Method (/article/1800)



AF Dibha,S Wahyuningsih,ANM Ansori,VD Kharisma,MH Widyananda,AA Parikesit,MT Sibero,RT Probojati,AAA Murtadlo,JP Trinugroho,TH Sucipto,DDR Turista,I Rosadi,ME Ullah,V Jakhmola,R Zainul

Pharmacognosy Journal,14(3):536-543

DOI: 10.5530/pj.2022.14.68

Published: Tue, 28-Jun-2022

[Read More \(/article/1800\)](#)



Original Article

Phytochemical Evaluation and Antioxidant Activity of Virginia tobacco Leaves (*Nicotiana tabacum* L. var *virginia*) Fractions with DPPH and FTC Methods ([/article/1791](#))

Kori Yati,Misri Gozan, ,Vivi Anggia,Rini Prastiwi,Mahdi Jufri

Pharmacognosy Journal,14(3):544-548

DOI: 10.5530/pj.2022.14.69

Published: Wed, 29-Jun-2022

[Read More \(/article/1791\)](#)



Original Article

In silico Analysis of the Polyphenolic Metabolites of *Zea mays* L. "Purple Corn" on HMG-CoA Reductase ([/article/1813](#))

Horna-Rodriguez Alexandra M,López-Gamboa July A,Silva-Correa Carmen R,Sagástegui-Guarniz William Antonio,Gamarra-Sánchez César D,Villarreal-La Torre Víc E

Pharmacognosy Journal,14(3):549-558

DOI: 10.5530/pj.2022.14.70

Published: Thu, 30-Jun-2022


[Read More \(/article/1813\)](#)



Research Article

Antioxidant and Cytotoxic Activities of Melinjo (*Gnetum gnemon* L.) Seed Fractions on HeLa Cell Line an In Vitro ([/article/1801](#))

Asep Sukohar, , ,Hendri Busman,Nuning Nurcahyani,Evi Kurniawaty



Pharmacognosy Journal,14(3):559-564

DOI: 10.5530/pj.2022.14.71


Published: Wed, 29-Jun-2022

[Read More \(/article/1801\)](#)

Research Article

Peel-off Mask Formulation from Stem of Sempeng (*Nepenthes gracilis*) as Anti Acne Against *Propionibacterium acnes* Bacteria (/article/1802)

Rezqi Handayani,Nurul Qamariah



Pharmacognosy Journal,14(3):565-570

DOI: 10.5530/pj.2022.14.72


Published: Wed, 29-Jun-2022

[Read More \(/article/1802\)](#)

Research Article

Azasterol Inhibition and Pharmacokinetic Effects on Thymidylate Synthase-Dihydrofolate Reductase from *T. gondii*: In Silico Study (/article/1803)

Alan Dharmasaputra, Annisa Uliya Rasyida



Pharmacognosy Journal,14(3):571-575

DOI: 10.5530/pj.2022.14.73


Published: Wed, 29-Jun-2022

[Read More \(/article/1803\)](#)

Research Article

Molecule Attachment and Prediction of ADMET Compounds in *Cinnamomum burmannii* on Orexin Receptor as Anti-insomnia (/article/1804)

Resmi Mustarichie,Nyi Mekar Saptarini,Sandra Megantara



Pharmacognosy Journal,14(3):576-583

DOI: 10.5530/pj.2022.14.74

Published: Wed, 29-Jun-2022



[Read More \(/article/1804\)](/article/1804)

Research Article

Alpha-Mangostin Enhances Proliferation in Sorafenib-Surviving HepG2 Liver Cancer Cells by Increasing Anti-Apoptosis and Antioxidant Markers Expressions (</article/1805>)


Melva Louisa, Meuthia Faralita Annisa, Pamela Basuki, Brigitta Cindy Lauren, Syarinta Adenina

Pharmacognosy Journal, 14(3):584-590

DOI: 10.5530/pj.2022.14.75

Published: Wed, 29-Jun-2022

[Read More \(/article/1805\)](/article/1805)



[\(/article/1805\)](/article/1805)

Research Article

Efficacy of Probiotic on Duodenal TNF- α Expression and the Histological Findings in the Liver and Lung in Animal Model Canine Coronavirus (</article/1806>)

Iwan Sahrial Hamid, Juni Ekowati, Rondius Solfaine, Shekhar Chhetri, Muhammad Thohawi El Purnama

Pharmacognosy Journal, 14(3):591-597

DOI: 10.5530/pj.2022.14.76

Published: Wed, 29-Jun-2022

[Read More \(/article/1806\)](/article/1806)



[\(/article/1806\)](/article/1806)

Research Article

In Vivo Studies of Combined Probiotics on IFN- γ , Ig-E and Bronchial Muscular Layer of Rats with Allergic Asthma (</article/1807>)


Pujiati Pujiati, ,Dono Indarto,

Pharmacognosy Journal, 14(3):598-603

DOI: 10.5530/pj.2022.14.77

Published: Wed, 29-Jun-2022

[Read More \(/article/1807\)](/article/1807)



[\(/article/1807\)](/article/1807)



Research Article

In Silico Phytochemical Compounds Screening of *Allium sativum* Targeting the Mpro of SARS-CoV-2 (/article/1808)

Priscilla Listiyani, Viol Dhea Kharisma, Arif Nur Muhamm Ansori, Muhammad Hermawan Widyananda, Rasyadan Taufiq Probojati, Ahmad Affan Ali Murtadlo, Dora Dayu Rahma Turista, Md. Emdad Ullah, Vikash Jakhmola, Rahadian Zainul



Pharmacognosy Journal, 14(3):604-609

DOI: 10.5530/pj.2022.14.78


Published: Wed, 29-Jun-2022

[Read More \(/article/1808\)](#)

Research Article

Standardization Study of Khurtsiin deed-6 Traditional Medicine (/article/1809)

,Purevsuren S, Chimedragchaa CH, Tserenkhand G, Norovnyam R



[\(/article/1809\)](#)

Pharmacognosy Journal, 14(3):610-621

DOI: 10.5530/pj.2022.14.79


Published: Wed, 29-Jun-2022

[Read More \(/article/1809\)](#)

Research Article

Pharmacobotany, Phytochemical Analysis and Anti-inflammatory effect of the Ethanolic Extract of *Luffa operculata* (/article/1810)

Jorge Alejandro Arroyo-Sandoval, Manuel Jesús Marin-Bravo, Jorge Luis Arroyo-Acevedo, Hugo Jesús Justil-Guerrero, Roberto Jesús Chávez-Asmat, Josefa Bertha Pari-Olarte, Javier Hernán Chávez-Espinoza, Jaime David Torres-Lévano, Eddie Loyola-Gonzales, José Santiago Almeida-Galindo, Oscar Herrera-Calderon



[\(/article/1810\)](#)

Pharmacognosy Journal, 14(3):622-628

DOI: 10.5530/pj.2022.14.80

Published: Wed, 29-Jun-2022

[Read More \(/article/1810\)](#)

Research Article



Role of Alkaloid on Platelet Aggregation and Serotonin in Migraine (/article/1811)

Olivia Mahardani Adam,Widjiati Widjiati

Pharmacognosy Journal,14(3):629-632

DOI: 10.5530/pj.2022.14.81

Published: Thu, 30-Jun-2022

[Read More \(/article/1811\)](#)



Research Article

Mangosteen (Garcinia mangostana L.): Evaluation of In Vitro Antioxidant Activities (/article/1814)


Defri Rizaldy,Nisrina Khairunnis Ramadhita,Trishna Nadhifa,Irda Fidrianny

Pharmacognosy Journal,14(3):633-640

DOI: 10.5530/pj.2022.14.82

Published: Thu, 30-Jun-2022

[Read More \(/article/1814\)](#)



[\(/article/1814\)](#)

Research Article

Phytochemical Screening, Gc-Ms Analysis and Antioxidant Activity of Marine Algae Obtained from Coastal Andhra Pradesh, India (/article/1815)

Swathi Priya K,Rajasekaran S

Pharmacognosy Journal,14(3):641-649

DOI: 10.5530/pj.2022.14.83

Published: Thu, 30-Jun-2022

[Read More \(/article/1815\)](#)



[\(/article/1815\)](#)

Research Article

Potential Anticancer Activity of Bioactive Compounds from Ipomoea batatas (/article/1816)

Carmen R. Silva-Correa,Julio Hilario-Vargas,Víctor E.Villarr La Torre,Abhel A. Calderón-Peña,Anabel D. González-Siccha,Cinthy L. Aspajo-Villalaz,José L. Cruzado-Razco



Pharmacognosy Journal,14(3):650-659

DOI: 10.5530/pj.2022.14.84


Published: Wed, 29-Jun-2022

[Read More \(/article/1816\)](#)

Research Article

Effects of Hyperbaric Oxygen Therapy on the Expression of FGF, MMP-9 and Occludin in the Repair of Gastric Mucosal Erosions (/article/1817)

Fathi Ilmawan, ,Guritno Suryokusumo,M. Miftahussurur



[\(/article/1817\)](#)

Pharmacognosy Journal,14(3):660-671

DOI: 10.5530/pj.2022.14.85


Published: Wed, 29-Jun-2022

[Read More \(/article/1817\)](#)

Research Article

Total Polyphenols, Total Flavonoids, Antioxidant Activity and Inhibition of Tyrosinase Enzymes from Extract and Fraction of Passiflora ligularis Juss (/article/1818)

Selvia Wiliantari,Raditya Iswandana,Berna Elya



[\(/article/1818\)](#)

Pharmacognosy Journal,14(3):672-680

DOI: 10.5530/pj.2022.14.86


Published: Mon, 11-Jul-2022

[Read More \(/article/1818\)](#)

Research Article

Evaluation of Antiviral Effects and Toxicity of Herbal Medicine Vipdervir Capsules (/article/1819)

Thi-Lien Nguyen,Huong Ha Thi Thanh,Kiet Ngo Tuan,Doan Cao Son,Thao Le Quang,Hang Nguyen Thi,Tien Vuong Duy,Quyen Doan Thi Tam,Huan Le Quang



[\(/article/1819\)](#)

Pharmacognosy Journal,14(3):681-689

DOI: 10.5530/pj.2022.14.87


Published: Wed, 29-Jun-2022



Research Article

Phytochemical Screening, In vitro Antioxidant Activities and Zebrafish Embryotoxicity of *Abelmoschus esculentus* Extracts (</article/1820>)

Veshalini K, Daryl Jesus Arapoc, Zainah Adam, Rosniza Razali, Noor Azuin Suliman, Noor Azlina Abu Bakar



[\(/article/1820\)](/article/1820)

Pharmacognosy Journal, 14(3):690-701

DOI: 10.5530/pj.2022.14.88

Published: Wed, 29-Jun-2022

[Read More \(/article/1820\)](/article/1820)

Research Article

Alpha-glucosidase and DPP-IV Inhibitory Activities of Ethanol Extract from *Caesalpinia sappan*, *Andrographis paniculata*, and *Syzygium cumini* (</article/1821>)

Sabila Robbani, Berna Elya, Raditya Iswandana



Pharmacognosy Journal, 14(3):702-709

DOI: 10.5530/pj.2022.14.89


Published: Wed, 29-Jun-2022

[Read More \(/article/1821\)](/article/1821)

Review Article

Potential Roles of Purslane (*Portulaca oleracea* L.) as Antimetabolic Syndrome: A Review (</article/1812>)

Nur Sofiatul Aini, Arif Nur Muhammm Ansori, Viol Dhea Kharisma, Muhammad Farraz Syadzha, Muhammad Hermawan Widyananda, Ahmad Affan Ali Murtadlo, Rasyadan Taufiq Probojati, Md. Emdad Ullah, Sin War Naw, Vikash Jakhmola, Rahadian Zainul



[\(/article/1812\)](/article/1812)

Pharmacognosy Journal, 14(3):710-714

DOI: 10.5530/pj.2022.14.90

Published: Wed, 29-Jun-2022

[Read More \(/article/1812\)](/article/1812)



SHARE THIS ARTICLE

EMAIL (MAILTO:?)
SUBJECT=PHARMACOGNOSY%20JOURNAL%2C%20%3CBR%20%2F%3EVOL%2014%2C%20ISSUE%203%2C%20MA
JUN%2C%202022&BODY=HTTPS%3A%2F%2FWWW.PHCOGJ.COM%2FV14%2F13)
(HTTPS://WWW.PHCOGJ.COM/ISSUE/3/2022/JUN/13)
U=HTTPS%3A%2F%2FWWW.PHCOGJ.COM%2FV14%2F13)
JUN%2C%202022&BODY=HTTPS%3A%2F%2FWWW.PHCOGJ.COM%2FV14%2F13)
HTTPS%3A%2F%2FWWW.PHCOGJ.COM%2FV14%2F13)

About

Pharmacognosy Journal (Phcog J.) covers different topics in natural product drug discovery, and also publishes manuscripts that describe pharmacognostic investigations, evaluation reports, methods, techniques and applications of all forms of medicinal plant research

Distinctions: The most widely read, cited, and known Pharmacognosy journal and website is well browsed with all the articles published. More than 50,000 readers in nearly every country in the world each month

ISSN : 0975-3575 ; Frequency : Rapid at a time publication (6 issues/year)

Indexed and Abstracted in : SCOPUS, Scimago Journal Ranking, Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Index Copernicus, Ulrich's International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.

Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.

Open Access Journal: Pharmacognosy Journal is an open access journal, which allows authors to fund their article to be open access from publication.

Submit your Next Article

- Online submission
- Highly indexed and abstracted
- 10 years of successful publishing
- Wider visibility though open access
- Higher impact with wider visibility
- Prompt review

Submit your next article to Phcog J



and be a part of many successful authors.

Create free account (<http://phcogj.info>)

/

Login

(<https://www.phcogj.com/submissions/index.php/phcogj/index>)

Copyright © 2020 Pharmacogn J. All rights reserved.

Pharmacognosy Journal and its contents are licensed under a Creative Commons Attribution-Non Commercial-No Derivs 4.0 License. Permissions beyond the scope of this license may be available with editor@phcogj.com (<mailto:editor@phcogj.com>)

[Home \(/\)](#)

[Advertise with us \(/\)](#)

[Privacy Statement \(/\)](#)



Toll Like Receptor 4 Expression Profile in Mice Infected Mycobacterium Tuberculosis Given with Miana Leaves Extract (*Coleus scutellarioides* (L.) Benth) (Tuberculosis Preventive and Curative Mechanisms)

Sesilia Rante Pakadang^{1,*}, St. Ratnah¹, Alfrida Monica Salasa¹, Jumain¹, Mochammad Hatta²

Sesilia Rante Pakadang^{1,*}, St. Ratnah¹,
Alfrida Monica Salasa¹, Jumain¹,
Mochammad Hatta²

¹Makassar Health Polytechnic Ministry of Health, INDONESIA.

²Faculty of Medicine, Hasanuddin University Makassar, INDONESIA.

Correspondence

Sesilia Rante Pakadang

Makassar Health Polytechnic Ministry of Health, INDONESIA.

E-mail: mamajassy@gmail.com

History

- Submission Date: 10-03-2022;
- Review completed: 01-04-2022;
- Accepted Date: 05-04-2022.

DOI : 10.5530/pj.2022.14.63

Article Available online

<http://www.phcogj.com/v14/i3>

Copyright

© 2022 Phcogj.Com. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

ABSTRACT

Introduction: Tuberculosis is an infectious disease of the respiratory tract caused by Mycobacterium tuberculosis. During Mycobacterium tuberculosis infection, pathogens modulate TLR-4 receptor flow signaling, suggesting possible involvement of TLR-4 in the regulation of the host immune response. This study aims to determine the effect of miana leaf extract on the expression of toll like receptor 4 (TLR-4) in tuberculosis mice at the preventive and curative stages. **Methods:** Mice were divided into 3 groups with 7x replication. Providing 14 days of preventive treatment, 14 days of incubation and 14 days of curative treatment. Group 1 and group 3 were given Miana Leaves Extract (EDM) and placebo at all three stages. Group 2 was given EDM at the preventive and incubation stages, then they were given anti-tuberculosis drugs (OAT). **Results:** The results proved that EDM given as a preventive did not increase the expression of TLR-4 protein in healthy mice; Changes in expression of TLR-4 protein in M.tb-infected mice before and after curative EDM increased by 17%, after administration of placebo increased 97% and decreased 12% after OAT curative administration; Changes in expression of TLR-4 protein in M.tb-infected mice before preventive administration and after EDM curative administration increased by 20%, after administration of placebo increased 102% and decreased by 10% after the curative administration of OAT. **Conclusions:** EDM has potential as antituberculosis with TLR-4 regulatory mechanism.

Key words: Miana Leaf, TLR-4, Antituberculosis.

INTRODUCTION

Tuberculosis is a respiratory tract infection caused by Mycobacterium tuberculosis (M.tb). M. tb bacteria through the inhalation process infects the host and causes the host to be infected with tuberculosis and has caused millions of deaths in various countries including Indonesia.¹⁻⁵ In addition to using anti-tuberculosis drugs, the tuberculosis healing process can also be complementary alternative medicine that involves the immune mechanism.⁶

Infection control of various pathogens such as M. tb depends on introducing the pathogen to lipopolysaccharides and activating innate and adaptive immune responses.⁷⁻¹⁴ Toll-like receptor (TLR) shows an important role in binding of several pathogens. Mycobacterial antigens recognize different TLRs that result in activation of innate / nonspecific immunity cells. The results of in vitro and in vivo investigations, show that TLR activation depends on the innate immune response,¹⁵ whereas the induction of adaptive immunity to mycobacteria does not change against TLR.¹⁶ Likewise, the miR-708-5p mechanism regulates mycobacterial vitality and inflammatory response in human macrophages by targeting TLR-4.¹⁷

During Mycobacterium tuberculosis infection, pathogens modulate TLR-4 receptor flow signaling, which suggests the possible involvement

of TLR-4 in the regulation of host immune responses. Mycobacterium indicus pranii (MIP) has immunomodulatory properties that induce a proinflammatory response via induction of TLR-4 mediated signaling, thus it was concluded that TLR4 could represent a new therapeutic target for activation of the innate immune response during tuberculosis infection.¹⁸

Macrophage activity against Mycobacterium tuberculosis has been shown to involve Toll-like receptor (TLR) activation and production of ROS. Lipopolysaccharide (LPS) is able to limit the negative effects of M.tb and increase bactericidal activity including phagocytosis, production of ROS, and destruction of M.tb. However, all these mechanisms are disrupted when TLR4 is inhibited.¹⁹

The process of preventing the spread or killing of M. tb bacteria in infected hosts occurs by the T-lymphocyte response mechanism to proliferate and stimulates CD4 T-cells especially the helper 1 T-cell subset to produce IFN- γ , TNF- α and several other cytokines such as IL. Furthermore, TNF- α will activate macrophages to form granulomas and carry out the process of killing bacteria.²⁰ Leaf extract of Miana (EDM) (*Coleus scutellarioides* (L.) Benth.) Has been shown to have potential as a preventive and complementary curative for tuberculosis by increasing the proliferation of T lymphocytes, CD4, IFN- γ , TNF- α thus reducing the number of M. tb colonies in the lungs.²¹

Cite this article: Pakadang SR, St. Ratnah, Salasa AM, Jumain, Hatta M. Toll Like Receptor 4 Expression Profile in Mice Infected Mycobacterium Tuberculosis Given with Miana Leaves Extract (*Coleus scutellarioides* (L.) Benth) (Tuberculosis Preventive and Curative Mechanisms). Pharmacogn J. 2022;14(3): 497-505.

Various attempts have been made by researchers to find solutions to eradicate tuberculosis, especially M.tb which has been resistant to standard drugs. Many studies have been conducted intensively to find new anti-tuberculosis drugs that can overcome M.tb drug resistance, tuberculosis infection in HIV patients and the risk of drug side effects due to the use of interacting tuberculosis drugs. One example of a drug that has been found is Delamanid with a mechanism of inhibiting mycobacterial cell wall synthesis and has been approved for use by the European Medicine Agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid is very potential as an antituberculosis with a small risk of drug interactions with better tolerability.²² These findings provide an idea to observe the effectiveness of herbal medicines that have been used empirically as antituberculosis by scientifically proven.

Miana leaf extract has been shown to be an immunomodulator, like *Mycobacterium indicus pranii* (MIP) which also has immunomodulatory properties that support the elimination of M.tb in macrophages through the TLR-4 receptor. In addition, EDM has also been proven as a hepatoprotector against anti-tuberculosis drugs in the treatment of tuberculosis.²³ So that research on the function of EDM as a preventive and curative in the treatment of tuberculosis based on the TLR-4 mechanism needs to be done.

MATERIALS AND METHODS

Preparation of test materials

Miana leaf test material was obtained from Tana Toraja Regency, South Sulawesi Province, Indonesia. The fresh leaves are sorted, chopped and then dried in an oven at 40-45^o C. The dried simplicia was extracted by maceration method and solvent evaporation using an evaporator. The thick extract of miana leaves obtained was used to identify alkaloids, saponins, flavonoids, tannins and polyphenols based on phytochemical screening and *in vivo* testing on mice (*Mus musculus*). The treatment dose of miana leaf extract was 714mg/kg body weight of mice.²¹ The comparison test material used anti-tuberculosis drugs (OAT) with the composition of rifampin 150 mg, ethambutol 275 mg, isoniazid 75 mg and pyrazinamide 400 mg. The dose of OAT treatment was calculated based on the conversion of the human dose to mice, namely 78mg/kg body weight of mice.

Identification of active compounds in miana leaves based on phytochemical screening

Phytochemical screening test using a color reaction with the appropriate reagent. **Alkaloid Test.** Extract ± 0.5 g + 2 mL ethanol 70% shaken + 5 mL HCl 2N, heated then added 3 drops of Mayer reagent to form a precipitate. **Saponin Test.** Extract ± 0.5 g + 2 mL 70% ethanol, shaken + 10 mL distilled water and shaken, then allowed to stand for 20 minutes. Then the solution causes foam. **Tannin Test.** Extract ± 0.5 g + 2 mL ethanol 70% shaken + FeCl₃ 1% 3 drops, a blue-black color occurs if the tannin compound is wrong and green-black color if the tannin compound is catechins. **Flavonoid Test.** Extract ± 0.5 g + 2 mL ethanol 70% shaken + 0.5 g magnesium powder and 3 drops of concentrated HCL. Formation of orange to red color indicates the presence of flavones, red to bright red indicates flavanols, bright red to purplish red indicates flavanones. **Polyphenol Test.** Ethanol extract + 10mL water and heated for 10 minutes, cooled and filtered. 3 drops of filtrate + FeCl₃ will form a purple to blue solution. **Tannin Test.** Extract 1 ml + 3 drops of FeCl₃ a green-blue black precipitate is formed. **Glycoside Test.** Extract 1 ml + 10 ml H₂SO₄ 50% then heated for 15 minutes. Next + Fehling's solution and heated until a brick red precipitate is formed. **Steroid Test.** Extract 1 ml + 10 ml concentrated H₂SO₄ will form a reddish solution.

Analysis of the total content of polyphenols and flavonoids

Testing the amount of polyphenol and flavonoid content is calculated based on the results of the absorption spectrophotometer. Total polyphenols based on gallic acid standards and total flavonoids were calculated based on the comparison of quercetin.

TLR-4 expression test after preventive and curative treatment

This research was conducted with the recommendation of ethical research approval from the Makassar Health Polytechnic of the Ministry of Health Number: 00159 / KEPK-PTKMKS / III / 2020. The study used 21 mice (*Mus musculus*) which were divided into 3 groups, namely Group K 1 (EDM), The K2 group (OAT, namely a combination of rifampin, ethambutol, isoniazid and pyrazinamide) and the K3 group (Placebo). The treatment of each group is as follows:

Group K 1: oral EDM (miana leaf extract) treatment once a day for 14 days (day 1-14) with a preventive dose of 357 mg / kg BW of mice. Then on the 14th day the mice were infected with M.tb suspension intraperitonium (equivalent to 10,000 colonies). Furthermore, the incubation period of 14 days (days 15-28) mice were still given EDM treatment with a preventive dose of 357 mg / kg of mice orally once a day.

Group K 2: oral EDM treatment (miana leaf extract) once a day for 14 days (day 1-14) with a preventive dose of 357 mg / kg BW of mice. Then on the 14th day the mice were infected with M.tb suspension intraperitonium (equivalent to 10,000 colonies). Furthermore, the incubation period of 14 days (days 15-28) mice were still given EDM treatment with a preventive dose of 357 mg / kg of mice orally once a day. Furthermore, 14 days (29-42 days) mice were given further treatment of anti-tuberculosis (OAT) drugs equivalent to Rifampisin dose of 78 mg / kg orally once a day.

Group K 3: oral placebo (Na CMC) treatment once a day for 14 days (day 1-14). Then on the 14th day the mice were infected with M.tb suspension intraperitonium (equivalent to 10,000 colonies). Furthermore, the incubation period of 14 days (days 15-28) mice were still given a placebo (Na CMC) orally once a day. Furthermore, 14 days (29-42 days) mice were given further treatment with placebo (Na CMC) orally once a day.

The first test blood sample was taken on day zero before the mice received treatment. The second test blood sample was taken on the 14th day (after being given preventive treatment) and the third test blood sample was taken on the 43rd day (after being given curative treatment). TLR4 testing using the ELISA method with Mouse Toll Like Receptor 4 (TLR4) ELISA Kit Cat. No: MBS026966. The data were analyzed by SPSS ANOVA and Least Significant Different method.

RESULTS AND DISCUSSION

Miana leaf extract yield and screening results

The simplicia of miana leaves from Tana Toraja Regency was macerated using 96% ethanol solvent and the yields listed in table 1 were obtained.

The results of phytochemical screening of the extract showed that the content of chemical compounds: alkaloids, glycosides, steroids, saponins, phenols, tannins, flavonoids. Polyphenol content 20.35mg / g EDM (gallic acid standard) and flavonoid content 7.35mg / g EDM (quercetin standard).

Test results of blood samples from mice

Blood collection of mice was carried out in 3 stages, namely




Table 1: Rendement of simplicia and miana leaf extract.

Source of miana leaf	Weight (grams)			Percentage	
	wet leaves	Extract yield	simplicia	extract	Extract yield
Tana Toraja Regency	4.000 grams	621 grams	500 grams	78.08 grams	15,62%

Stage 1 (blood sample 1) day zero before the mice were given preventive treatment.

Stage 2 (blood sample 2) on the 14th day after the mice received preventive treatment before the mice were given Mycobacterium tuberculosis infection.

Stage 3 (blood sample 3) on the 42nd day after the mice experienced the incubation phase of infection and were given curative treatment.

DISCUSSION

Research has been carried out using test animals Balb C strain, as one of the suitable mammals for use in preclinical testing. *Mus musculus* (mice) are called house mice and belong to the group of mice. The use of rat test animals, especially transgenic mice, is often used for preclinical testing, especially the body's immune mechanism because there is a similarity between the human immune system and mice, namely having strong natural immunity.²⁴ In addition to selecting the right experimental animal, the number of uses of tested animals also plays a very important role in determining the quality of research data. This study used replication of 7 mice tested animals according to the results of the calculation of the number of replications for a sample of 3 groups. The calculation of the number of samples plays a role in the research design including studies using test animals. If replication using small numbers of animals tends to produce non-significant data. However, if the number of replications is too large, it will be problematic with research ethics due to waste of test animal resources.²⁵

One of the factors that is a critical point in this study is the process of taking blood from test animals. Since blood sampling is carried out for up to 3 periods during the treatment period, the animal must be made comfortable or avoid stress. The stress level of the tested animals can cause changes in the physiology and immunology of the tested animals so that it has an impact on the measured test parameter values of each test animal. Collecting blood samples from experimental animals should not stress the animals, which in turn has an impact on the

results of the study. In this case, a permit from the Institute's Animal Ethics Committee is required to be submitted and approved before conducting treatment.²⁶ This study also obtained approval from the institutional ethics commission before starting treatment.

The selection of miana leaf test material is a part of the miana plant obtained from Tana Toraja Regency. The basis for selecting the source of the test material is based on the content of active substances and antioxidant potential, the potential for previously proven immunomodulators.²¹ The results of the screening test in this study proved that the secondary metabolites in EDM were steroids, glycosides, saponins, phenols, flavonoids, alkaloids and tannins. Secondary metabolites in EDM function as antibacterials with various mechanisms such as immunostimulants, cytokine immunodepressants, inhibiting cell DNA synthesis, agglutinating proteins, damaging cell wall membranes.^{23,27-29} The use of OAT as antituberculosis takes 3 months, 6 months and even 9 months. The length of the treatment period allows side effects that cause treatment to be interrupted and cure is not achieved. Overcoming this requires herbal medicine that can support safe long-term treatment of tuberculosis. Previous research stated that EDM has the potential to be a hepatoprotector against liver function and organ damage in tuberculosis treatment using rifampin.²³ Furthermore, also concluded the EDM toxicity with an LD50 value of ethanol extract of 9757.14 mg / kg body weight of mice.³⁰

This study discusses the effect of giving miana leaf extract (EDM) on the prevention and cure of tuberculosis with the toll like receptor 4 (TLR-4) protein expression mechanism. The choice of TLR-4 protein expression mechanism is because TLR-4 is related to the bacteriocidal mechanism of Mycobacterium tuberculosis by macrophages. Macrophage activity against Mycobacterium tuberculosis has been shown to involve Toll-like receptor (TLR) activation and production of ROS. Previous research has shown that lipopolysaccharide, through TLR4, can activate macrophages, increase the production of ROS which are bacteriocidal, and facilitate anti-infective immune responses.¹⁹

The effect of EDM on the expression of TLR-4 was observed in 3 stages, namely preventive, curative and preventive curative. This study used a controlled placebo test and anti-tuberculosis drugs (OAT). The OAT used is a combination of 4 types of drugs that are used as standard drugs in the treatment of tuberculosis. OAT contains (rifampin, ethambutol, Isoniazide and pyrazinamide). The preventive phase was observed when the mice were still healthy before and after being given EDM maintenance. The preventive objective was to determine the natural effect of EDM on TLR-4 expression, so that the differences in TLR-4 expression when mice were sick and healthy could be compared. The curative stage was observed before and after the mice were infected with Mycobacterium tuberculosis and were given EDM, OAT and placebo treatment. This stage was used to observe the effect of treatment on recovery, in this case the removal of tuberculosis bacteria from the body of sick mice based on TLR-4 expression and animal comparisons that were given placebo. The preventive curative stage was observed before being given EDM as maintenance and after the mice were given EDM as a treatment. The aim of this stage is to prove the potential of EDM as an herb to prevent tuberculosis infection and as a complement to tuberculosis treatment.

OAT is a standard drug in the treatment of tuberculosis which contains several types of drugs with an antibacterial function (bacteriostatic and bactericide). The study compared the function of OAT with herbal medicine, namely EDM to determine the potential of EDM as a preventive against tuberculosis infection and complementary in the treatment of tuberculosis. The function of EDM as an antibacterial tuberculosis has been previously studied which states that EDM is effective as an antibacterial for M.tb. The function of EDM as complementary in the treatment of tuberculosis produces immunomodulatory potentials that increase the proliferation of T lymphocytes, T cells, IFN- γ , TNF- α .²¹ Furthermore also proven the potential of EDM as a complementary treatment for tuberculosis by increasing IL-6 mRNA expression and decreasing IL-10 mRNA expression.²⁷ The potential of these cytokines can support the function of macrophages to swallow and eliminate M.tb in the lungs and blood, thus providing healing for the host. The function of cytokines that play a role in eliminating bacteria is related to the function of TLR-4 as a receptor on macrophages to ingest M.tb.

Expression of TLR-4 at the preventive stage

The preventive observation was carried out by taking two blood samples, namely before and after giving EDM and placebo as test materials. The EDM dose as maintenance was 357 mg / kg BW in mice. This dose is converted from previous research where EDM can function as an immunomodulator in the prevention of tuberculosis.²¹ Placebo was given as a control comparison of EDM effects to determine differences in the results of TLR-4 expression. TLR-4 expression was observed before and after preventive treatment to determine the effect of EDM administration in a healthy state to prevent tuberculosis infection. Previous studies have stated that the results of *in vivo* and *in vitro* investigations show that TLR activation depends on the innate immune response.^{15,16}

The results of the observations in Table 2 indicate that all mice express TLR-4 naturally. Table 3 shows the changes in TLR-4 expression at the preventive stage where the administration of EDM and placebo increased the number of TLR-4 in healthy conditions. This shows that the immune function involving TLR-4 can be activated when cells are influenced from outside the body, for example in this case EDM. However, under normal conditions or no Mycobacterium tuberculosis infection, the increase in TLR-4 should not be as excessive as in EDM administration in this study. When the response to TLR-4 expression is excessive it allows an over-response of immunity that is not needed under normal circumstances because it can activate cytokines excessively when not needed. In this study, the provision of EDM

which is immunomodulatory is able to regulate the immune response as needed by showing differences in TLR-4 expression as a preventive which is not significantly different before and after treatment. Thus the TLR-4-mediated immune response such as cytokines, NO, TNF α and others does not occur when it is not needed. Hosts who live together with tuberculosis sufferers need to have a good immune defense to prevent tuberculosis and other infections from the environment. EDM has the potential as an immunomodulator to prevent tuberculosis infection by increasing the proliferation of T lymphocytes, T cells, IFN- γ , TNF- α .²¹ Where it is known that these cytokines are needed as a preventive and can be activated *via* the TLR-4 receptor on M.tb-sensitized macrophages or other pathogens. This is consistent with the conclusions of Das *et al.* (2016)¹⁸ who stated that increasing TLR-4 can activate cytokines, NFkB, NO and P38 MAP when M.tb.

Expression of TLR-4 at the curative stage

The observations at the curative stage showed that the TLR-4 values were different before and after the curative treatment. The condition of group 3 mice (the group given placebo) changed from healthy to sick due to M.tb infection given. Illness was evidenced by the increased expression of TLR-4 which significantly changed from the start and end of infection. This is because M.tb which infects the host (mice) triggers host immunity activity in macrophages to inhibit growth, eliminating the presence of M.tb and killing M.tb in host cells. Host immunity to fight M.tb infection involves macrophages to recognize, ingest and eliminate M.tb and stimulate macrophage activation involving TLR-4 as pathogen binding receptors. The results of this study are in line with research which states that the survival of M.tb will increase miR-21-5p expression and expression of miR-708-5p and attenuates the secretion of inflammatory cytokines such as IL-6 and TNF- α in macrophages involving TLR-4 as a target pathogen in macrophages.^{17,31}

In contrast to the placebo group that was not given post-infection treatment, in groups 1 and 2 after which mice were infected with M.tb, they were given treatment after the incubation period. The treatment given was EDM for group 1 and OAT (a combination of rifampin, ethambutol, pyrazinamide and isoniazid) for group 2. The results showed that the expression of TLR-4 before infection and after treatment was significantly different. Likewise, Table 4 shows the significant differences in changes in TLR-4 expression between the groups treated with placebo. The number of TLR-4 expressions in the group given placebo was very high compared to the group given treatment. Placebo TLR-4 expression was 9.7 times that of the OAT group and 5.5 times that of the EDM group. This means that EDM treatment provides a healing effect of tuberculosis infection with a potential of 57% of the potency of OAT. This potential is very promising because the OAT used is a combination of 4 types of drugs (rifampin, ethambutol, INH and pyrazinamide), while EDM is a single extract. Cure of infection in this study was related to TLR-4 expression because TLR-4 is a receptor on macrophages for the recognition and destruction of the pathogen M.tb. This is in line with the research who concluded that TLR-4 could represent a new therapeutic target for activating innate immune responses during tuberculosis infection.^{14,18}

When a pathogen infects the host, the body activates macrophages at the TLR-4 receptor to modulate other immune responses such as IL-6 (interleukin 6), IL-1 β (interleukin 1 β), IFN- γ (interferon gamma) and TNF- α (tumor necrosis factor alpha).³² This study showed that levels of TLR-4 expression in the placebo group increased by 97%, whereas those in the OAT-treated group increased by 12% and EDM increased by 19%. These data show the potential of EDM as an antibacterial which is very promising, considering that one dose of EDM gives an effect close to the potency of OAT which is a combination of 4 doses of anti-tuberculosis drugs. Analysis of these data is possible when EDM is given as a complement to OAT in the treatment of tuberculosis so that it can

Table 2: Expression of TLR-4 protein at stages 1,2 and 3.

Treatment group	n	TLR-4 expression level (ng / ml)					
		Blood sample 1		Blood sample 2		Blood sample 3	
		Mean	SD	Mean	SD	Mean	SD
K1	7	393,9702	32,9676	402,5116	41,9432	471,5744	58,2291
K2	7	397,3929	54,7211	407,2096	61,8159	358,3238	46,2681
K3	7	385,325	63,6832	394,4692	52,3806	776,7678	40,3707

K1: group 1 (mice were given EDM as a preventive and curative)
 K2: group 2 (mice were given EDM as a preventive and OAT as a curative)
 K3: group 3 (mice were given Na CMC as a placebo for preventive and curative)

Table 3: Changes in expression of TLR-4 before and after preventive.

Treatment group	n	Changes in levels of TLR-4 (ng / ml)				
		Mean	SD	Median	Min	Maks
K1a -K1b	7	8,546	25,991	17,71	-23,726	40,818
K2a -K2b	7	9,874	19,349	19,92	-14,152	33,899
K3a -K3b	7	9,142	39,326	9,142	-39,687	57,971

a is a blood sample 1
 b is a blood sample 2
 K1a -K1b: blood sample 1 and blood sample 2 from group 1
 K2a -K2b: blood sample 1 and blood sample 2 from group 2
 K3a -K3b: blood sample 1 and blood sample 2 from group 3

Table 4: The LSD test results of changes in TLR-4 expression before and after curative.

Treatment group	n	Changes in levels of TLR-4 (ng / ml)				
		Mean	SD	Median	Min	Maks
K1b -K1c	7	69,06	30,245	79,66	31,5058	106,614
K2b -K2c	7	-48,89	28,6512	40,85	-84,4653	-13,3147
K3b -K3c	7	382,3	54,6368	378,4	314,459	450,14

b is a blood sample 2
 c is a blood sample 3
 K1b -K1c: blood sample 2 and blood sample 3 from group 1
 K2b -K2c: blood sample 2 and blood sample 3 from group 2
 K3b -K3c: blood sample 2 and blood sample 3 from group 3

Table 5: The LSD test results of changes in TLR-4 expression before prevention and after curative.

Treatment group	n	Changes in levels of TLR-4 (ng / ml)				
		Mean	SD	Median	Min	Maks
K1a -K1c	7	77,606	46,5376	66,39	19,821	135,39
K2a -K2c	7	-39,016	31,4815	-24,34	-78,105	-0,0735
K3a -K3c	7	391,442	67,5449	402,74	307,573	475,31

a is a blood sample 1
 c is blood sample 3
 K1a -K1c: blood sample 1 and blood sample 3 from group 1
 K2a -K2c: blood sample 1 and blood sample 3 from group 2
 K3a -K3c: blood sample 1 and blood sample 3 from group 3

Table 6: Percentage change in expression of TLR-4 at each treatment stage.

Groups	Percentage change in expression of TLR-4 at each treatment stage (%)		
	Preventive	Curative	Preventive Curative
Group 1	2	17	20
Group 2	2	-12	-10
Group 3	2	97	102

Group 1: a group of mice given EDM
 Group 2: a group of mice given OAT
 Group 3: the group of mice given a placebo
 positive: increased TLR-4 expression
 negative: decreased TLR-4 expression

reduce the dose of OAT. So that it can further reduce the side effects of treatment. In line with this study, it was stated that giving C4T4 agonists could increase immunity and reduce the amount of M.tb from the lungs of mice infected with M.tb. So that the combined use of C4T4 agonists and OAT (isoniazid or rifampin) can reduce the dosage of OAT by up to 10 times lower than using C4T4 alone to provide the same effect. The mechanism that occurs is that complementary C4T4 and OAT can reduce TLR-4 even though the dose of OAT is reduced by 10 times.³³ Thus, it can be stated that TLR-4 is a parameter of the condition of the host infected with tuberculosis which can be lowered by the combined administration of OAT and complementary EDM for the treatment of tuberculosis. Evidence that the combination of rifampin and OAT was able to kill M.tb colonies to zero compared to OAT alone, still found the colony count was 81.67 CFU / g and EDM alone was found to be 187.5 CFU / g at the end of treatment based on the results tuberculosis rat lung culture.²¹ The number of colonies in the end is a parameter of the host's recovery from tuberculosis and one of the factors that play a role in the elimination of M.tb is TLR-4. The increase in TLR-4 is needed when the host is infected to activate immunity against infection but will decrease again with elimination of the pathogen in the host.

Expression of TLR-4 at the preventive curative stage

Treatment at the preventive curative stage analyzed differences in the expression of TLR-4 protein at the beginning of the preventive treatment and after treatment. In this stage the mice as hosts experienced a period of EDM administration in preventive doses before experiencing infection, then received curative dose EDM treatment after going through the infection incubation stage. The results of the observation show that the provision of EDM and OAT has an effect on the expression of TLR-4 because it is significantly different from giving placebo according to table 5. Data showed an increase in the expression of TLR-4 before preventive and after successive curative for EDM increased 20%, OAT decreased 10% and placebo increased 102%. This proves that the placebo group the host experienced active infection because of the very high expression of TLR-4. The increase in TLR-4 expression in the EDM and OAT groups was significantly different from the placebo group. LSD analysis showed that giving EDM was significantly different from giving OAT to TLR-4 expression. The results in table 1 show that giving OAT can return the state of the host infected with tuberculosis to normal as it was based on its TLR-4 expression which is not significantly different.

Analysis of the results of EDM treatment as a preventive during the incubation period has been shown to support the ability of host immunity to limit the spread of infection. In this case the expression of TLR-4 at the preventive stage before infection and during the incubation period after tuberculosis infection has been shown to have the potential to activate the immune system as an initial defense when infection occurs. Initial defense is important to restrain the rate of infection during the incubation period and support the elimination of bacteria during the curative period. The administration of preventive doses of EDM given during the incubation period was proven to activate macrophages to recognize, ingest and eliminate M.tb which involved TLR-4 as a receptor. TLR-4 which is sensitized by the pathogen M.tb can further promote the activation of proinflation cytokines such as IFN- γ , IL-6, IL-1 β and TNF- α .³⁴ Thus the growth of M.tb during the incubation period is limited. These findings can be applied to healthy hosts who live together or are in an environment with active tuberculosis sufferers. The function of EDM as a preventive can activate the production of proinflammatory cytokines such as IFN- γ and TNF- α for the prevention of tuberculosis.²²

The analysis of the results of curative preventive observations proves the potential of EDM as a preventive has supported the success of tuberculosis treatment using OAT. Differences in TLR-4 expression

before preventive and after treatment showed significantly different levels between treatment with EDM or with OAT. It is known that OAT is a combined drug of 4 types of anti-tuberculosis with therapeutic doses of each drug, however, EDM provides a curative potential that is close to the curative potential of using OAT. The analysis for these data is based on the content of active substances or secondary metabolites such as flavonoids from EDM which support their antibacterial function. The flavonoid content of 7.35mg / g EDM and total polyphenols of 20.35mg / g EDM is a promising amount as an active component of the miana plant (*Coleus scutellarioides* (L.) Benth.). Flavonoids as antioxidants can be immunostimulant and antibacterial in general, including M.tb. Various evidences have been gathered to prove the mechanism of flavonoids as anti-tuberculosis. All flavonoids from plants, especially the flavone and flavonone groups have been proven to be antimikobacterial, anti-M.tb or anti-tuberculosis.²⁹

The findings in this study were the potential of EDM as a preventive and curative for tuberculosis based on TLR-4 expression. This is evident based on the expression of TLR-4 from the EDM group approaching the OAT group but very low compared to the placebo group, especially after curative. The role of TLR-4 in modulating the body's defenses against mycobacterial infections has provided new information about the pathogenesis of tuberculosis thus providing useful assumptions for developing potential therapeutic interventions for disease.³⁵

CONCLUSION

EDM given as a preventive does not increase the expression of TLR-4 protein in healthy mice.

Changes in expression of TLR-4 protein in M.tb-infected mice before and after curative EDM increased by 17%, after giving placebo increased 97% and decreased 12% after OAT curative administration.

Changes in expression of TLR-4 protein in mice infected with M.tb before preventive administration and after EDM curative administration increased by 20%, after administration of placebo increased 102% and decreased by 10% after OAT curative administration.

SUGGESTION

It is recommended to carry out further research to determine the potential use of miana leaves as a complementary treatment for infectious diseases, especially tuberculosis with B cell antibody mechanisms.

ACKNOWLEDGEMENTS

Thank you to the Director, Research and Community Service Unit of the Makassar Health Polytechnic Ministry of Health for financial support and support for researchers in carrying out this research. Thanks also go to all the staff of the molecular biology and immunology laboratory, Hasanuddin University Medical School.

AUTHORS CONTRIBUTION

Sesilia Rante Pakadang as the lead author and other writers took part in the research at each stage. All authors contributed to each stage of the study.


CONFLICTS OF INTEREST

There are no conflicts of interest.

1. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, *et al.* Tuberculosis. In Nature Reviews Disease Primers. 2016;2:16077.
2. Zumla A, Raviglione M, Hafner R, Fordham von Reyn C. Tuberculosis. New England Journal of Medicine. 2013.
3. Diel R. Treatment of tuberculosis. Pneumologie. 2019.

4. Ingersoll MA, Platt AM, Potteaux S, Randolph GJ, Mantovani A, Sozzani S, et al. Supplementary information. *Immunity*. 2012.
5. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The epidemiology, pathogenesis, transmission, diagnosis and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. In *The Lancet Respiratory Medicine*. 2017;S2213-2600(17)30079-6.
6. Faujdar J, Gupta P, Natrajan M, Das R, Chauhan DS, Katoch VM, et al. Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis. *Indian Journal of Medical Research*. 2011;134(5):696-703.
7. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. In *Cytokine*. 2008.
8. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. *Journal of Immunology* (Baltimore, Md: 1950). 1999;162(7):3749-52.
9. Park BS, Lee JO. Recognition of lipopolysaccharide pattern by TLR4 complexes. In *Experimental and Molecular Medicine*. 2013;45(12):e66.
10. Laird MHW, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ, et al. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. *Journal of Leukocyte Biology*. 2009;85(6):966-77.
11. Seki E, De Minicis S, Österreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF- β signaling and hepatic fibrosis. *Nature Medicine*. 2007;13(11):1324-32.
12. Wang X, Liu C, Wang G. Propofol Protects Rats and Human Alveolar Epithelial Cells Against Lipopolysaccharide-Induced Acute Lung Injury via Inhibiting HMGB1 Expression. *Inflammation*. 2016;39(3):1004-16.
13. Akira S, Takeda K. Toll-like receptor signalling. In *Nature Reviews Immunology*. 2004.
14. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. In *Frontiers in Immunology*. 2014.
15. Takeda K, Yamamoto M. Current views of toll-like receptor signaling pathways. In *Gastroenterology Research and Practice*. 2010;2010:240365.
16. Quesniaux V, Fremont C, Jacobs M, Parida S, Nicolle D, Yermeev V, et al. Toll-like receptor pathways in the immune responses to mycobacteria. *Microbes and Infection*. 2004;6(10):946-959.
17. Li WT, Zhang Q. MicroRNA-708-5p regulates mycobacterial vitality and the secretion of inflammatory factors in Mycobacterium tuberculosis-Infected macrophages by targeting TLR4. *European Review for Medical and Pharmacological Sciences*. 2019;23(18):8028-8038.
18. Das, Shibali, Chowdhury BP, Goswami A, Parveen S, Jawed J, et al. Mycobacterium indicus pranii (MIP) mediated host protective intracellular mechanisms against tuberculosis infection: Involvement of TLR-4 mediated signaling. *Tuberculosis*. 2016;101:201-209.
19. Jingzhu L, Xiaoyan He, Wang H, Wang Z, Kelly GT, Wang X, et al. TLR4-NOX2 axis regulates the phagocytosis and the phagocytosis and killing Mycobacterium tuberculosis by macrophages. *BMC Pulmonary Medicine*. 2017;17(1):194.
20. Van Crevel R, Kleinnijenhuis J, Oosting M, Joosten LAB, Netea MG. Innate immune recognition of mycobacterium tuberculosis. In *Clinical and Developmental Immunology*. 2011;2011:405310.
21. Pakadang SR, Wahjuni CU, Notobroto HB, Winarni D, Dwiyanti R. Immunomodulator Potential of Miana Leaves (*Coleus scutellarioides* (L.) Benth) in Prevention of Tuberculosis Infection. 2015;3(4):129-134.
22. Xavier AS, Lakshmanan M. Delamanid: A new armor in combating drug-resistant tuberculosis. *Journal of Pharmacology and Pharmacotherapeutics*. 2014;5(3):222-4.
23. Pakadang SR, Sinala S, Dewi STR, Soemantoro H, Hilaria M. Subchronic toxicity and hepatoprotector potential of miana leaf extract on white rat which indicated by anti tuberculosis drugs. *Indian Journal of Forensic Medicine and Toxicology*. 2020.
24. Baratawidjaja KG, Rengganis I. *Imunologi Dasar*. edisi ke-10. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia. 2010.
25. Charan J, Kantharia N. How to calculate sample size in animal studies? In *Journal of Pharmacology and Pharmacotherapeutics*. 2013;4(4):303-306.
26. Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. *Journal of Pharmacology and Pharmacotherapeutics*. 2010.
27. Palette T, Hatta M, As'ad CS, Alam G. Effect of Purple Miana Leaf (*Coleus Scutellarioides* (L) Benth) from Tana Toraja District on IL-10 mRNA Expression in Mice Induced Mycobacterium Tuberculosis. *International Journal of Sciences: Basic and Applied Research (IJSBAR) International Journal of Sciences: Basic and Applied Research*. 2017.
28. Anita A, Arisanti D, Fatmawati A. Potensial Of Flavonoid Miana (*Coleus Atropurpureus*) Leaves Estract As Anti Mycobacterium Tuberculosis H37rv Strain And Mdr With Microscopy Observation Drug Susceptibility (Mods). *Jurnal Ilmu Alam Dan Lingkungan*. 2018.
29. Nayem N, Imran M, Bawadekji A. Review Article Flavonoids: A Potential Group of Phytoconstituents against Mycobacterial. *Journal of the North for Basic and Applied Sciences (JNBAS)*. 2018;3(1):44-62.
30. Ridwan Y, Satrija F, Handharyani E. Toksisitas Akut Ekstrak Daun Miana (*Coleus Blumei* Benth) pada Mencit (*Mus Musculus*). *Acta VETERINARIA Indonesiana*. 2020.
31. Zhonghua Z, Jinzhu H, Xia L, Yanfang C, Xiaoyan Q. MiR-21-5p regulates mycobacterial survival and inflammatory responses by targeting Bcl-2 and TLR4 in Mycobacterium tuberculosis-infected macrophages. *FEEBS Letters*. 2019;593(12):1326-1335.
32. Shang T, Zhang X, Wang T, Sun B, Deng T, Han D. Toll-like receptor-initiated testicular innate immune responses in mouse leydig cells. *Endocrinology*. 2011;152(7):2827-36.
33. Pahari S, Negi S, Aqdas M, Arnett E, Schlesinger LS, Agrewala JN. Induction of autophagy through CLEC4E in combination with TLR4: an innovative strategy to restrict the survival of Mycobacterium tuberculosis. *Autophagy*. 2020;16(6):1021-1043.
34. Shi G, Mao G, Xie K, Wu D, Wang W. MiR-1178 regulates mycobacterial survival and inflammatory responses in Mycobacterium tuberculosis-infected macrophages partly via TLR4. *Journal of Cellular Biochemistry*. 2018;119(9):7449-7457.
35. Zhi M, Zhang AR, Zhang M, Xu J, Lou W, Qiang Q. TLR-4/miRNA-32-5p/FSTL1 signaling regulates mycobacterial survival and inflammatory responses in Mycobacterium tuberculosis-infected macrophages. *Experimental Cell Research*. 2017;352(2):313-321.

GRAPHICAL ABSTRACT



ABOUT AUTHORS



Dr. Sesilia Rante Pakadang, M.Si, Apt was born in Sinjai, September 22, 1969. She studied from bachelor to master at Hasanuddin University. Doctoral education is completed at Airlangga University. Have expertise in the field of Microbiology and Immunology. Now as a permanent lecturer in the Department of Pharmacy Health Polytechnic Makassar Ministry of Health Republic of Indonesia. Active in various research in the field of medicinal herbs, especially for infectious diseases. Productive in writing practical guide books, guides for making herbal products, and writing articles in various publications.



St. Ratnah, S.Si., M.Kes. born in Pangkep December 10, 1977. He studied microbiology at Hasanuddin University. As a lecturer in the Department of Pharmacy Health Polytechnic Makassar Ministry of Health Republic of Indonesia and teaches microbiology, pharmacognosy and immunology courses. Actively conducts research in the field of medicinal plants and makes herbal products and writes articles in international publications and proceedings.



Alfrida Monica Salasa, was born in Ujung Pandang, April 01, 1981. Completed her Masters study in the Biomedical Sciences Study Program at Hasanuddin University. Permanent lecturer at the Department of Pharmacy of Health Polytechnic, Ministry of Health, Makassar. The subject taught is the field of Microbiology. Research focus on traditional medicinal plants. Has produced several publications.



Drs. Jumain, M.Kes, Apt, was born in Lampa, November 16, 1963. A senior lecturer in pharmacology in the Department of Pharmacy, Health Polytechnic Makassar Ministry of Health Republic of Indonesia. He is active as a researcher in the pharmacology of traditional Indonesian medicinal plants and has published many articles in several national journals. In 2009 as outstanding lecturer of national level in the Ministry of Health Republic of Indonesia



Prof. Mochammad Hatta, MD, PhD, Clinical Microbiologist (Cons) is professor of Molecular Biology and Immunology for Infectious Diseases it in Medical Faculty, Hasanuddin University. Makassar, Indonesia since 1985. His MD degree from Medical Faculty, Hasanuddin University Makassar and completed PhD in Faculty of Medicine, Toyama Medical and Pharmaceutical Univ, Japan. He is holding a Chairman and Consultant as chairman of Post Graduate School, Medical Faculty, Hasanuddin University, Indonesia.

Cite this article: Pakadang SR, St. Ratnah, Salasa AM, Jumain, Hatta M. Toll Like Receptor 4 Expression Profile in Mice Infected *Mycobacterium Tuberculosis* Given with Miana Leaves Extract (*Coleus scutellarioides* (L.) Benth) (Tuberculosis Preventive and Curative Mechanisms). *Pharmacogn J.* 2022;14(3): 497-505.